Licensing

All articles by Licensing

Novo Nordisk doles out $1.4B for molecular glue degraders licensing pact
Novo Nordisk doles out $1.4B for molecular glue degraders licensing pact
Jack O'Brien
February 26, 2024
3:46 pm

The Danish pharma giant will provide Neomorph with an upfront payment as well as near-term milestone payments in addition to funding for research and development.

BridgeBio sells partial rights to dwarfism drug for $100M
BridgeBio sells partial rights to dwarfism drug for $100M
Marc Iskowitz
February 8, 2024
4:05 pm

The upfront payment pads BridgeBio’s balance sheet as the company gears up for the anticipated launch of another drug, ATTR-CM med acoramidas.

GSK strikes deal with Hansoh Pharma worth up to $1.7B for ADC asset
GSK strikes deal with Hansoh Pharma worth up to $1.7B for ADC asset
Jack O'Brien
December 20, 2023
12:51 pm

The exclusive license agreement will give GSK rights to Hansoh’s HS-20093, a B7-H3 targeted ADC that’s being investigated in several cancers.

FTC cows Sanofi into giving up on Maze licensing deal
FTC cows Sanofi into giving up on Maze licensing deal
Marc Iskowitz
December 12, 2023
3:32 pm

Sanofi backed away from its drug-licensing deal with Maze Therapeutics after the Federal Trade Commission moved to block the deal. However, the rest of the biotech industry isn’t taking it lightly.

Eli Lilly scoops up Beam’s licensing rights in Verve deal for $250M
Eli Lilly scoops up Beam’s licensing rights in Verve deal for $250M
Jack O'Brien
October 31, 2023
1:01 pm

Notably, the Lilly deal is also expected to extend Beam’s cash runway to the second half of 2026.

AbbVie terminates collaboration with I-Mab on CD47 antibody compounds
AbbVie terminates collaboration with I-Mab on CD47 antibody compounds
Jack O'Brien
September 25, 2023
10:51 am

The deal will be terminated effective November 20, 2023, with the global rights to develop and commercialize certain CD47 compounds and products, including lemzoparlimab, returned to I-Mab.

AbbVie ditches license option for Harpoon’s TriTAC multiple myeloma program
AbbVie ditches license option for Harpoon’s TriTAC multiple myeloma program
Jack O'Brien
September 14, 2023
11:17 am

Going forward, Harpoon said the TriTAC multiple myeloma program will remain exclusively within the company as it plans to complete an ongoing Phase 1 clinical trial with data to support the next phase of development.

GSK signs in-license agreement with LimmaTech for shigella vax candidate
GSK signs in-license agreement with LimmaTech for shigella vax candidate
Jack O'Brien
July 20, 2023
3:19 pm

LimmaTech also named Franz-Werner Haas as its CEO.

Janssen strikes $245M licensing deal with Cellular Biomedicine Group for CAR-T cancer therapies
Janssen strikes $245M licensing deal with Cellular Biomedicine Group for CAR-T cancer therapies
Lecia Bushak
May 2, 2023
4:35 pm

Janssen’s licensing agreement with Cellular Biomedicine Group will give it access to two CAR-T assets, including C-CAR039.

Sanofi, Maze strike $150M licensing deal for glycogen synthase 1 program
Sanofi, Maze strike $150M licensing deal for glycogen synthase 1 program
Lecia Bushak
May 1, 2023
3:51 pm

Sanofi is bolstering its rare disease pipeline in the move and will pay up to $600 million in milestones.

  • From Our Partners